NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Provision Holding, Inc. (OTCQB: PVHO) with a price target of $0.60.

The report is available here: PVHO Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

The report describes that Provision is an intriguing speculative company in the technology sector that specializes in 3D holographic media. Provision has developed a portfolio of 3D holographic digital signage, which is deployed in hundreds of kiosks in retail stores throughout major markets in the US – including many deployments at one of the nation’s largest retailers, Rite Aid. Provision management gave a presentation at SeeThruEquity’s Innovations Conference on February 22, co-hosted with the Brewer Group in Miami, FL, with CEO Curt Thornton describing the impressive turnaround Provision has made over the last year and outlining the remarkable growth in deployments being experienced by Provision with its largest retail outlet. Thornton highlighted the rapid growth Provision is experiencing in its kiosk deployments, with over 450 kiosks deployed so far in FY16, and expectations that total kiosks shipped will more than double to reach 1,000 by the end of FY16.

Highlights from the report are as follows:

Deployments accelerating in retail with large potential pipeline

In the last several quarters, however, Provision appears to have gained momentum in the retail market, with 200 kiosk installations and $3.4mn in revenues reported in the first two quarters of FY16, versus $0.6mn in revenue in FY15. Provision confirmed it has already completed another 250 installations, bringing the total to 450 kiosks as of February 2016. In our view, the company’s rising revenues and installations could be a sign that Provision and the 3D hologram market may have finally arrived. Indeed, while we still expect Provision to require new capital beyond the recently announced $4mn convertible debt raise, we see several catalysts ahead for the company. Management has outlined a steady growth trajectory to 1,000 fully functioning kiosk deployments in FY16 and has also stated that it sees potential for an additional 3,500 kiosk installations. We also expect the company to receive increased notoriety from the recent endorsement of its 3D kiosks by Intel, and longer term growth from new retail locations and penetration into new markets such as video gaming, home entertainment, automotive, education, telecommunications and medical imaging, which management has estimated represents a multi-billion dollar opportunity for the company.

Technology appears to be received favorably in early deployments

Provision’s 3D holographic technology platform is integrated with in-store kiosks to project floating 3D holographic images in the air – detached from the screen without the assistance of any mist or requiring 3D glasses. Provision’s current kiosk platform uses 3D holograms at the top, with a 2D touchscreen at the bottom – enabling customers access to special rewards that can be added to their loyalty accounts in real time for use. Our initial take is that Provision’s technology appears to be being received favorably, based on follow-on installations in Rite Aid and comments by Intel in a recent whitepaper, entitled Tomorrow’s Digital Signage Today with 3D Holographic Kiosks, which stated that Provision’s 3D holographic technology in combination with Intel business intelligence solutions is “forever changing how retailers and brands target and engage their customers.”

Initiate coverage with a price target of $0.60

Our analysis indicates a fair value estimate of $0.60 per share (detailed on pages 9-10) for Provision. We see Provision as a promising speculative growth story in technology, offering a nice combination of easy-to-understand technology with apparently strong near-term demand from retail kiosk shipments. If achieved, the price target of $0.60 represents potential upside of 233% from the recent price of $0.18.

Please review important disclosures at www.seethruequity.com.

About Provision Interactive Technologies, Inc.

Provision Interactive Technologies, Inc., a subsidiary of the publicly traded company Provision Holding, Inc. (PVHO), is the leading purveyor of intelligent interactive 3D holographic display technologies, software, and integrated solutions for both commercial and consumer focused applications.

Provision’s 3D holographic display systems represent a revolutionary technology that provides the projection of full color, high-resolution videos into space detached from the screen, without any special glasses. Provision is currently the market leader in true 3D consumer advertising display products being implemented by innovative, consumer-focused companies.

Provision Holding, Inc. (PVHO) trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 440680

LOS ANGELES, CA / ACCESSWIRE / June 2, 2016 / Social Reality, Inc. (OTCQB: SCRI), an Internet advertising and platform technology company that provides tools to automate the digital advertising market, today announced that it will be presenting at the 6th annual LD Micro Invitational on Tuesday June 7, 2016 at 1:00/PM PT / 4:00PM ET.

Social Reality’s CEO Christopher Miglino will deliver the Company’s corporate presentation and discuss recent business highlights. In addition to the presentations, management will also be available for one-on-one meetings. To arrange a one-on-one meeting with management, please contact Robert Haag at scri@irthcommunications.com or 1-866-976-4784.

To access webcast, participants may visit: http://wsw.com/webcast/ldmicro10/scri

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small / micro-cap space.

View Social Reality’s profile here: http://www.ldmicro.com/profile/SCRI

Profiles powered by LD Micro – News Compliments of Accesswire

About Social Reality

Social Reality, Inc. is an Internet advertising company that provides tools to automate the digital advertising market. The company has built technologies and leveraged partner technologies that service social media and the Real Time Bidding (RTB) markets. For more information, please visit www.socialreality.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Robert Haag, Managing Director
Company: IRTH Communications
Phone: 866-976-4784
Email: SCRI@irthcommunications.com

SOURCE: Social Reality via LD Micro

ReleaseID: 440663

VANCOUVER, BC / ACCESSWIRE / June 2, 2016 / Vendetta Mining Corp. (TSXV: VTT) (“Vendetta” or the “Company”) is pleased to announce that it has commenced drilling activities on the Pegmont Lead-Zinc Project located in the Mount Isa region of Queensland, Australia.

Phase 1 drilling will focus on the near surface sulphide mineralization at the Burke Hinge Zone (“BHZ”) and on Zone 5 which has demonstrated higher zinc grades, highlights of which can be found in Table 1 below.

The objectives of the program are:

• Complete Phase 1 drilling in the BHZ and Zone 5 for a total of 4,600 m in 25 drill holes;
• Complete metallurgical flotation test work on the BHZ and Zone 5;
• Update the NI 43-101 Mineral Resource Estimate, including for the first time the BHZ and Zone 5 during Q4 2016.

Located on a granted Mining Lease, mineralization at the BHZ outcrops and plunges shallowly to the south west with sulphide mineralization starting 24 m below surface. The BHZ was initially drilled in 1996 with further drilling conducted by Vendetta in the 2014 program resulting in the discovery of a tight anticline structure that has a significant accumulation of lead-zinc mineralization in the fold hinge. The BHZ is currently drilled on a nominal 15-20 m hole spacing on 45 m sections.

Vendetta conducted its initial exploration drilling in Zone 5 in 2014. The program confirmed the presence of a second mineralized horizon and demonstrated that the zinc grade increases in Zone 5 – confirming the Company’s geological model for the Pegmont deposit. Zone 5 has a known strike of 500 metres and is located between 110 and 380 m below surface, it is open down-dip and along strike. The Company will also undertake a minor program of shallow reverse circulation (“RC”) drilling on regional exploration targets.

Vendetta Retains Former MMG Metallurgist

To oversee the metallurgical program, the Company has retained the services of Geoff Richmond, an accomplished metallurgist with over 45 years of mineral processing experience. Most recently, Mr. Richmond spent 6 years as Principal Metallurgist at MMG Limited and its predecessor companies. He was project metallurgist during the detailed engineering phase at Las Cruces Mine in Spain (now First Quantum) and was Laboratory Manager at one of Australia’s leading metallurgical laboratories which is now part of the ALS Metallurgy group in Tasmania, Australia. Prior to these appointments Mr. Richmond spent 14 years working in operations and process improvement at the Hellyer Zinc-Lead-Copper mine, a significant zinc and lead producer at the time.

Vendetta’s President and CEO, Mr. Williams stated, “we are pleased to add a metallurgist of Mr. Richmond’s caliber to our growing team. His experience will allow us to maximize each phase of the metallurgical program.”

The Company will be releasing results over the course of the program.

About Pegmont

The Pegmont lead-zinc-silver deposit is located in North West Queensland Mineral Province, 175 km south-east of the major mining center of Mount Isa, and 28 km west of South32’s world class Cannington silver-lead-zinc operation and 25 km north of Chinova Resources’ Osborne and Kulthor copper-gold operations. It is proximate to infrastructure including roads, rail, and natural gas for power generation.

Pegmont is a multiple lens, stratiform Broken Hill style deposit that outcrops with an overall shallow dip to the south east and is hosted in a magnetite rich banded iron formation within high grade metamorphic rocks. The project consists of three granted mining leases and two exploration permits that cover an area of approximately 3,468 ha.

Highlights of the drill results from Burke Hinge Zone and Zone 5 are presented in Table 1 below and the February 2014 NI 43-101 Mineral Resource Estimate on Zones 1 to 4 in Table 2.

Table 1.     Highlights of the Burke Hinge Zone and Zone 5 Sulphide Drilling, which are not included in the February 2014 NI 43-101 Mineral Resource Estimate.

 

Note: For full details about the above drill results please see the Company’s previous news releases on the 15th October 2014, 28th January 2015 and 10th February 2015.

Table 2. February 2014 Pegmont Zone 1 – 4 Mineral Resource Estimate*.

*Reference: “Technical Report Pegmont Property Mineral Resource Estimate” AMC Mining Consultants (Canada) Ltd, effective date of 28 February 2014. The Technical Report is available on SEDAR.

Notes on Table 2:

1. CIM definitions were used for the Mineral Resources.
2. The cut-off grade applied to the oxide and transition Mineral Resources is 3% Pb + Zn, the sulphide cut-off grade is 5% Pb + Zn.
3. Cut off is based on $0.90 /lb for Pb and Zn, a $0.90 A$:US$ exchange rate, and 90% recovery for both metals.
4. Specific gravity used by oxidation state: 3.2 t/m³ oxide, 3.4 t/m³ transition and 3.9 t/m³ sulphide.
5. Using drilling results to 12 December 2013.

About Vendetta Mining Corp.

Vendetta Mining Corp. is a Canadian junior exploration company engaged in acquiring, exploring, and developing mineral properties with an emphasis on lead and zinc. It is currently focused on advanced stage exploration projects in Australia, the first of which is the recently optioned Pegmont Lead Zinc project. Additional information on the Company can be found at www.vendettaminingcorp.com

Qualified Person

Peter Voulgaris, MAusIMM, MAIG, a Director of Vendetta, is a non-independent qualified person as defined by NI 43-101. Mr. Voulgaris has reviewed the technical content of this press release, and consents to the information provided in the form and context in which it appears.

ON BEHALF OF THE BOARD OF DIRECTORS

“Michael Williams”

Michael Williams
President & CEO
1.604.484.7855

Forward Looking Information

This news release includes forward-looking statements that are subject to risks and uncertainties.  Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements.

Disclaimer

All statements within, other than statements of historical fact, are to be considered forward looking. Although Vendetta Mining Corp. believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include: the completion of the full exploration program for which the use of proceeds is geared toward, the accuracy of exploration results, the accuracy of Mineral Resource Estimates, the anticipated results of future exploration, the forgoing ability to finance further exploration, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release and as such, accepts no responsibility for the adequacy or accuracy of this release.

SOURCE: Vendetta Mining Corp.

ReleaseID: 440679

Coastal Compassion has Started Construction on Its Registered Medical Dispensary in Fairhaven, MA

DENVER, CO / ACCESSWIRE / June 2, 2016 / AmeriCann, Inc. (OTCQX: ACAN), a company that designs, develops and leases sustainable, state-of-the-art medical cannabis cultivation properties, has begun funding a loan as part of a definitive agreement with Coastal Compassion, Inc. in Massachusetts.

Through AmeriCann’s Preferred Partner Program, Coastal Compassion will be the first tenant in AmeriCann’s proposed Massachusetts Medical Cannabis Center located in Freetown, MA. In addition, AmeriCann is providing consulting support during the construction of Coastal Compassion’s approved dispensary in Fairhaven, Massachusetts.

JoAnne Leppanen, Executive Director of Coastal Compassion, stated, “We are excited to start construction on our dispensary and make progress towards providing high quality, affordable medical cannabis to Massachusetts patients.”

Coastal Compassion is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health.

The 10,000 square foot building in Fairhaven will house Coastal Compassion’s dispensary, which has been provisionally approved by the State. The Fairhaven facility has a Special Permit and Building Permit from the Town of Fairhaven and architectural approvals from the Department of Public Health. Once complete, the facility will begin servicing patients while AmeriCann completes the development of the Massachusetts Medical Cannabis Center.

The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. Coastal Compassion finalized agreements to occupy the first phase of the project that consists of an initial 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., for Coastal Compassion based on patient demand.

“AmeriCann and Coastal Compassion share a commitment to delivering patients unsurpassed medicine produced with sustainable practices,” stated AmeriCann founder and CFO Ben Barton. “The commencement of this loan towards the completion of Coastal’s medical dispensary in Fairhaven is simply the first step in a long-term partnership in serving patients in the Commonwealth.”

The Massachusetts Medical Use of Marijuana Program, which was approved by voters in 2012 by a wide margin, continues to be one of the premier regarded markets by industry experts even with the first dispensaries having only recently opened.

A ballot initiative to allow for full marijuana legalization has received the necessary signatures and is expected to be on the November 2016 ballot for Massachusetts voters. “The state (Massachusetts) could become one of the biggest regulated cannabis markets in the country; bigger than Colorado and Washington State,” according to Marijuana Business Daily.

About AmeriCann

Americann is a publicly traded company that designs, develops and leases sustainable, state-of-the-art medical cannabis cultivation properties. The Company has over 1,000,000 square feet of facilities in various stages of development. AmeriCann has preferred partners in Colorado, Massachusetts and Delaware. AmeriCann does not cultivate, process or distribute cannabis, but partners with local business to serve marijuana patients in their communities. More information about the Company is available at: www.americann.co.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise.

Contact Information:

Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co

Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878

SOURCE: AmeriCann, Inc.

ReleaseID: 440674

MADISON, WI and LOS ANGELES, CA / ACCESSWIRE / June 2, 2016 / Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 6th annual LD Micro Invitational on Thursday, June 9 at 9:30 AM PST/12:30 PM EST. Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.

“As we continue to successfully advance our operating plan and clinical programming, we remain committed to providing performance updates with existing and potential shareholders,” said Mr. Caruso. “The LD Micro Invitational conference provides an excellent venue to further share the Cellectar story and we are appreciative of the opportunity to participate.”

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small/micro-cap space.

View Cellectar Biosciences’ profile here: http://www.ldmicro.com/profile/CLRB

Profiles powered by LD Micro – News Compliments of Accesswire

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC Delivery Platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For additional information please visit www.cellectarbiosciences.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

SOURCE: Cellectar Biosciences via LD Micro

ReleaseID: 440662

HENDERSON, NV / ACCESSWIRE / June 2, 2016 / Rainbow Coral Corp. (OTCQB: RBCC) continues to seek new opportunities and breakthroughs in personalized medicine and recent news from Singapore could offer the company the ground floor chance it has been looking for to become a leader in this rapidly growing field.

Scientists in the southeast Asian nation have announced they have invented a means to 3D print medications customized to suit individual
patients’ unique needs. These tablets release drugs at specific (or personalized) timetables, or profiles, geared to the patient. The scientists, working at the National University of Singapore, say manufacturing the
personalized pills via 3D printing is simple, versatile and inexpensive.

RBCC CEO Kimberly Palmer said, “This latest breakthrough in personalized medicine could lead to much more effective treatments and better overall health.”

“This is an exciting breakthrough, both for medicine and for a company like ours,” she said.

“With timed-release pills like these,” Palmer explained, “those patients who tend to forget to take their medications can now get the full benefit of their prescriptions. This painlessly and easily solves the longstanding problem of patient compliance. For RBCC, this could be the opportunity we’ve been looking for to become a leader in the field. We’ll be examining how to get into the manufacture of such pills and will be seeking potential partners also interested in this revolutionary process.”

According to one published report, the personalized medicine market is expected to top $88 billion by 2022. 3D printing is a booming market on its own, with analysts predicting that industry will surpass $20 billion by
2020.

For more information on RBCC’s initiatives, please visit www.rainbowbiocorp.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.rainbowbiocorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO
info@rainbowcoral.com

SOURCE: Rainbow Coral Corp.

ReleaseID: 440677